CSL Seqirus

What CSL Seqirus does

CSL Seqirus is a business division of CSL Limited, an Australian publicly listed biotechnology company, and operates as one of the world's largest influenza vaccine providers. The company was created in 2015 when CSL acquired the influenza vaccine business from Novartis, deriving its name from the expression 'securing health for all of us.' Its portfolio centers on seasonal influenza vaccines — Fluad (an MF59-adjuvanted vaccine for older adults and vulnerable populations), Flucelvax (a cell-based quadrivalent vaccine), and Afluria — together with pandemic preparedness products such as Audenz (an H5N1 vaccine), antivenoms, Q-fever vaccine, and the recently listed neffy epinephrine nasal spray. Manufacturing is conducted on three continents at facilities in Melbourne/Tullamarine (Australia), Holly Springs (North Carolina, USA), and Cambridge (UK), with R&D in Waltham, Massachusetts. CSL Seqirus distinguishes itself through proprietary cell-based influenza vaccine manufacturing (one of only three countries globally with end-to-end capability, per the company's disclosure) and MF59 adjuvant technology, with a new $1 billion Melbourne cell-based facility opened in December 2025.

The company sells primarily through government procurement contracts and public health distribution systems — pandemic preparedness contracts with the Public Health Agency of Canada (capacity to cover Canada's entire ~41.5 million population), bilateral agreements with the Government of Australia, and technology transfer / supply partnerships with PAHO and Sinergium in Latin America (up to 400 million doses annually by 2028). Seasonal vaccine distribution flows to healthcare providers and public health immunization programs. The pending separation from CSL Limited as an independent ASX-listed entity was announced in August 2025 but delayed in October 2025 due to US influenza vaccination rate declines and expected mid-teens percentage revenue decline for FY26. The company is concurrently executing a 15% group-wide workforce reduction (~4,350 employees) and cost restructuring of $500-550M annually. Gordon Naylor, former Seqirus president, was appointed interim CEO of CSL Limited in February 2026, underscoring Seqirus's strategic importance within the parent group.

Name

CSL Seqirus

Legal name

CSL Seqirus

Website

https://cslseqirus.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

CSL Seqirus is one of the world's largest influenza vaccine providers, offering seasonal (Fluad, Flucelvax, Afluria) and pandemic (Audenz) vaccines plus antivenoms to government health agencies and healthcare providers across the Americas, Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Influenza Vaccines and Biopharmaceuticals

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD)

akta.pro secondary industries

Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Influenza vaccines
• Cell-based manufacturing
• Pandemic preparedness
• Adjuvanted vaccines
• Antivenom production

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Seasonal Influenza Vaccines: Sale of seasonal influenza vaccines including Fluad (adjuvanted), Flucelvax (cell-based), and Afluria through government procurement and healthcare provider channels.
2. Pandemic Preparedness Contracts: Government contracts for pandemic influenza vaccine preparedness, including agreements with Public Health Agency of Canada for cell-based adjuvanted influenza vaccines contingent on WHO pandemic declaration.
3. Specialty Vaccine Products: Market for Afluria and other CSL Seqirus influenza vaccine products projected to grow driven by increased influenza prevalence, vaccination policies, and demographic shifts.
4. Technology Transfer and Licensing: Technology transfer agreements enabling regional vaccine production capacity in Latin America through PAHO collaboration, generating potential exports and regional manufacturing capabilities.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

CSL Seqirus manufactures and supplies a broad portfolio of seasonal and pandemic influenza vaccines, including adjuvanted (Fluad), cell-based (Flucelvax), and standard (Afluria) products, alongside the H5N1 pandemic vaccine Audenz. The division also produces Australia's eleven antivenom products, a Q-fever vaccine, and the neffy epinephrine nasal spray for emergency anaphylaxis treatment, selling primarily to government health agencies, public health systems, and healthcare providers worldwide.

Product overview

CSL Seqirus operates as one of the world's largest influenza vaccine providers, offering a broad portfolio of seasonal and pandemic influenza vaccines along with complementary emergency medications and antivenoms. The core product portfolio centers on seasonal influenza vaccines including Fluad (adjuvanted with MF59 technology), Flucelvax (cell-based), and Afluria, complemented by pandemic preparedness products such as Audenz (H5N1 vaccine). The company has also expanded into emergency medications with neffy (epinephrine nasal spray for anaphylaxis) and maintains production of antivenoms and Q-fever vaccine. The recent $1 billion Melbourne manufacturing facility makes Australia one of only three countries globally with end-to-end cell-based influenza vaccine manufacturing capability.

Differentiator

Problem solved

Functional benefit

Brands

• Fluad: Adjuvanted seasonal influenza vaccine
• Flucelvax
• Afluria
• Audenz
• Afluria (CSL Seqirus)

Products and services

• Fluad
• Flucelvax
• Afluria
• Audenz
• Neffy
• Antivenoms
• Q-fever Vaccine

Quantifiable outcome

• Pandemic vaccine production capacity of 150M+ doses in first wave
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Pan American Health Organization (PAHO) - Long-term AgreementcoreStrategic or Co-development Partner · 12 May 2026CSL Seqirus signed a long-term agreement with PAHO's Regional Revolving Fund for pandemic influenza preparedness in Latin America and the Caribbean. The agreement builds on the parties' seasonal influenza collaboration to support rapid and scalable pandemic response capabilities.
• Public Health Agency of Canada (PHAC)coreStrategic or Co-development Partner · 9 March 2026PHAC awarded CSL Seqirus a contract to produce cell-based adjuvanted influenza vaccines for pandemic preparedness, with capacity to manufacture over 150 million doses in the first wave of production - enough to cover Canada's entire population of approximately 41.5 million people. The agreement marks a strategic shift from PHAC's previous egg-based influenza vaccine contracts to cell-based manufacturing.
• Government of CanadacoreStrategic or Co-development Partner · 6 March 2026New pandemic preparedness contract to supply millions of doses of cell-based adjuvanted influenza vaccines for pandemic preparedness, contingent on a WHO pandemic declaration. The agreement replaces a previous egg-based vaccine contract and builds on the successful six-year integration of cell-based Flucelvax into Canada's seasonal influenza program.
• Pan American Health Organization (PAHO)coreStrategic or Co-development Partner · 6 March 2026PAHO announced a technology transfer agreement with CSL Seqirus and Sinergium to establish cell-based influenza vaccine production in Argentina. The new platform, expected to be operational by 2028 with capacity for up to 400 million doses annually, marks a shift from traditional egg-based methods to more advanced technology. Argentina already supplies about half of seasonal influenza vaccines for countries in Americas through PAHO's Revolving Fund.
• SinergiumcoreStrategic or Co-development Partner · 6 March 2026Sinergium partnered with CSL Seqirus and PAHO to establish cell-based influenza vaccine production in Argentina. The partnership aims to build manufacturing capacity for up to 400 million doses annually by 2028, with potential to generate up to $250 million in annual exports.
• Government of Australia (Prime Ministers Carney-Albanese)coreStrategic or Co-development Partner · 5 March 2026Bilateral agreement including renewed pandemic vaccine preparedness contract for up to 15 million doses from CSL Seqirus's Australian manufacturing facility, signed during Canadian Prime Minister Carney's first official visit to Australia.
• World Health Organization (WHO)minorStrategic or Co-development PartnerCSL participates in WHO initiatives related to pandemic preparedness and global health security. The WHO has been involved in influenza vaccine strain selection and pandemic preparedness frameworks that affect CSL Seqirus operations.
• World Federation of Hemophilia (WFH)minorStrategic or Co-development PartnerCSL supports WFH Humanitarian Aid Program to bring needed medicines to underserved parts of the world for people with bleeding disorders. CSL also supports the WFH Path to Access to Care and Treatment (PACT) Program to advance diagnosis, enhance training and advocacy.

Scale indicators10 records

Recent moves10 records

Expansion highlights4 records

Direct peers

• Sanofi (Sanofi Pasteur): Sanofi Pasteur is one of the world's largest influenza vaccine manufacturers, directly competing with CSL Seqirus across seasonal flu (Efluelda) and pandemic preparedness. The two are currently locked in an EU antitrust dispute over Sanofi's marketing practices toward Fluad, underscoring the intensity of head-to-head competition.
• GSK: GSK is a major global influenza vaccine manufacturer (Fluarix, FluLaval) and competes directly with CSL Seqirus in both seasonal flu and pandemic preparedness tenders across government and healthcare provider channels.
• Pfizer: Pfizer is one of the largest global vaccine manufacturers with a significant influenza franchise, including pandemic preparedness supply. It competes with CSL Seqirus for government pandemic contracts and seasonal vaccine tenders, particularly in the US market where Seqirus is seeing the most revenue pressure.

Emerging players

• Moderna: Moderna is developing mRNA-based seasonal and pandemic influenza vaccines that could compete with CSL Seqirus's cell-based platform. While not yet a major incumbent in flu, its mRNA technology represents a credible next-generation challenger in the same procurement and clinical channels.
• BioNTech: BioNTech is advancing mRNA-based influenza vaccine candidates leveraging its COVID-19 vaccine platform expertise. While its commercial flu product is not yet established, it represents a credible emerging threat to cell-based and traditional flu vaccine manufacturers including CSL Seqirus.
• Novavax: Novavax develops nanoparticle protein-based vaccines including influenza candidates, positioning it as a next-generation challenger in the same pandemic preparedness and seasonal flu markets where CSL Seqirus competes.
• Bharat Biotech: Bharat Biotech is an Indian vaccine manufacturer with growing global ambitions across influenza and other vaccines. It participates in PAHO tenders and other emerging-market procurement programs where CSL Seqirus also competes, making it a partial peer in international vaccine supply.

Regional players

• Daiichi Sankyo: Daiichi Sankyo is a major Japanese pharmaceutical company that manufactures and supplies influenza vaccines domestically, including cell-based products. It is a relevant regional peer in Asia-Pacific, an important market for CSL Seqirus, though it does not directly compete in the Americas or Europe.
• Sinovac Biotech: Sinovac is a leading Chinese vaccine manufacturer with influenza vaccine offerings primarily serving the domestic and broader Asian markets. It is a regional peer relevant to CSL Seqirus's expansion ambitions in Asia-Pacific and influenza pandemic preparedness.

Broad incumbents

• AstraZeneca: AstraZeneca is a large global biopharmaceutical company with significant vaccine capabilities (including pandemic preparedness contracts with governments post-COVID) and broad infectious disease infrastructure. While not a pure-play flu competitor, it is a broad incumbent in adjacent vaccine and pandemic preparedness markets where CSL Seqirus competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/csl
• YouTubeyoutube.com/user/CSLGroup
• Facebookfacebook.com/CSLBiotechnology
• LinkedInlinkedin.com/company/csl
• Instagraminstagram.com/cslbiotechnology

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSL Seqirus